Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuzuru Inoue is active.

Publication


Featured researches published by Yuzuru Inoue.


Diseases of The Colon & Rectum | 2007

Lymphatic Microvessel Density is an Independent Prognostic Factor in Colorectal Cancer

Kentaro Matsumoto; Yoshifumi Nakayama; Yuzuru Inoue; Noritaka Minagawa; Takefumi Katsuki; Kazunori Shibao; Yosuke Tsurudome; Keiji Hirata; Naoki Nagata; Hideaki Itoh

PurposeAlthough lymph node metastasis via lymphatic vessels often is related with an adverse outcome, it is not well known whether lymphatic spread to lymph node needs the development of the new lymphatic formation. In addition, the correlation between lymphangiogenesis and prognosis has not been well documented. This study was designed to assess the prognostic value of lymphangiogenesis and lymphatic vessel invasion in colorectal cancer.MethodsWe examined 106 colorectal cancer specimens by immunostaining for podoplanin, lymphatic endothelial specific marker. We evaluated lymphangiogenesis, as measured by lymphatic microvessel density, and lymphatic vessel invasion. We next investigated the association of these two parameters with the clinicopathologic findings and prognosis.ResultsA significant correlation was observed between high lymphatic microvessel density and positive lymphatic vessel invasion (P = 0.0003). Positive lymphatic vessel invasion was significantly associated with the presence of lymph node metastasis (P = 0.0071). The survival curves demonstrated that both high lymphatic microvessel density and positive lymphatic vessel invasion were correlated with an adverse outcome (P = 0.0004 and P = 0.009, respectively). In a univariate analysis, high lymphatic microvessel density and positive lymphatic vessel invasion were negatively associated with the overall survival (P = 0.0011 and P = 0.0118, respectively). Furthermore, high lymphatic microvessel density, but not lymphatic vessel invasion, correlated with a poor outcome in a multivariate analysis (P = 0.0114).ConclusionsOur data suggested that lymphatic vessel invasion was related with lymph node metastasis and that both lymphatic microvessel density and lymphatic vessel invasion were related with an adverse outcome in colorectal cancer. Furthermore, lymphatic microvessel density may be a useful prognostic factor in colorectal cancer.


Oncology Research | 2004

4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor.

Noritaka Minagawa; Yoshifumi Nakayama; Yuzuru Inoue; Koji Onitsuka; Takefumi Katsuki; Yosuke Tsurudome; Kazunori Shibao; Keiji Hirata; Tatsuhiko Sako; Naoki Nagata; Shinji Ohie; Kimitoshi Kohno; Hideaki Itoh

4-[3,5-bis(trimethylsilyl)benzamido] Benzoic acid (TAC-101) has potent antiproliferative, antiangiogenic, and antitumor effects in vitro and in vivo. These effects might be due to TAC-101 binding to retinoic acid receptor alpha (RAR-alpha) and interfering with the binding of activator protein-1 (AP-1) to DNA. However, little is known about the detailed mechanism of TAC-101 function. We investigated the mechanism of the antiangiogenic effect of TAC-101 using a rat hepatic metastatic model in vivo and DLD-1 human colon cancer cells in vitro. Liver metastases were induced by portal injection of RCN-9 rat colonic cancer cells into F344 rats. TAC-101 (8 mg/kg) was orally administered 5 days per week for 4 weeks and then hepatic tumors were immunohistochemically evaluated for microvessel density (MVD) and vascular endothelial growth factor (VEGF). TAC-101 significantly reduced both MVD and VEGF expression. Northern blot analysis and ELISA indicated that TAC-101 efficiently inhibited production of VEGF mRNA and protein in DLD-1 cells in a time- and dose-dependent manner. These findings suggest that TAC-101 may inhibit progression and metastasis in colon cancer by interfering with tumor production of VEGF.


Journal of UOEH | 2018

甲状腺の胸腺様分化を示す癌Carcinoma Showing Thymus-Like Differentiation(CASTLE)of the Thyroidの1例

Yuzuru Inoue; Shiro Kohi; Masato Gobara; Fumi Joden; Kei Yabuki; Takayuki Tanoue; Nagahiro Sato; Takefumi Katsuki; Takahisa Nagata; Kazunori Shibao; Masanori Hisaoka; Keiji Hirata

The case presented herein was a 70-year-old woman who had no compliant, but had a mass in the lower part of the right lobe of the thyroid detected by ultrasound (US). The US image of the tumor, measuring 13 mm in diameter, showed a low and heterogeneous internal echo level with calcification and an irregular margin. The tumor appeared to extend to the adjacent sternothyroid muscle, and cervical lymph node swelling was detected in a computer tomography (CT) image, but no metastatic lesion was found by positron emission tomography (PET)-CT. In a fine needle aspiration cytology of the tumor, papillary thyroid carcinoma was suggested because of the atypical epithelial cells having some changes other than intranuclear inclusion bodies. A subtotal thyroidectomy and central neck lymph node dissection were performed. The excised tumor was histologically composed of irregular nests or sheets of atypical squamoid epithelial cells with some ductal structures that leached to the sternothyroid muscle and involved the right lower parathyroid gland. Carcinoma showing thymus-like differentiation (CASTLE) was diagnosed histopathologically and immunohistochemically with the following immunohistochemical results: Cluster of differentiation 5 (CD5) (+), tumor protein p63 (p63) (+), KIT proto-oncogene receptor tyrosine kinase (c-KIT(CD117)) (+), thyroglobulin (-), and thyroid transcription factor-1 (TTF-1) (-). CASTLE is a rare carcinoma of the thyroid that architecturally resembles thymic epithelial tumors. Many CASTLE patients have been misdiagnosed as other carcinomas, such as anaplastic carcinoma, poorly differentiated carcinoma or squamous cell carcinoma of the thyroid. Immunohistochemical examination, including CD5 played an important role in the final diagnosis of CASTLE, although the distinction from diagnosis as squamous cell carcinoma or mucoepidermoid carcinoma in Hematoxylin-Eosin staining was challenging in our case. Nodal metastasis and perithyroidal tumor extension of CASTLE can predict its worse prognosis. Thus, at least careful follow-up studies are mandatory in cases of CASTLE.


Asia-pacific Journal of Clinical Oncology | 2018

The prognostic significance of the expression of monocarboxylate transporter 4 in patients with right- or left-sided colorectal cancer

Yukio Abe; Yoshifumi Nakayama; Takefumi Katsuki; Yuzuru Inoue; Noritaka Minagawa; Takayuki Torigoe; Aiichiro Higure; Tatsuhiko Sako; Naoki Nagata; Keiji Hirata

Monocarboxylate transporter 4 (MCT4) is a proton pump that exchanges lactate through the plasma membrane. The present study investigated the clinical significance of the expression of MCT4 in patients with right‐ or left‐sided colorectal cancer (CRC).


European Radiology | 2017

Evaluation of the R2* value in invasive ductal carcinoma with respect to hypoxic-related prognostic factors using iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL)

Mari Miyata; Takatoshi Aoki; Shohei Shimajiri; Atsuji Matsuyama; Shunsuke Kinoshita; Masami Fujii; Takefumi Katsuki; Yuzuru Inoue; Yoshika Nagata; Yuko Tashima; Yukunori Korogi

ObjectiveTo correlate the R2* value obtained by iterative decomposition of water and fat with echo asymmetry and least-squares emission (IDEAL) with fibrotic focus (FF), microvessel density and hypoxic biomarker (HIF-1α) in breast carcinoma.MethodsForty-two patients who were diagnosed with invasive ductal carcinoma (IDC) of the breast underwent breast MRI including IDEAL before surgery. The entire region of interest (ROI) was delineated on the R2* map, and average tumour R2* value was calculated for each ROI. Histological specimens were evaluated for the presence of FF, the microvessel density (the average microvessel density and the ratio of peripheral to central microvessel density), and the grading of HIF-1α.ResultsFF was identified in 47.6% (20/42) of IDCs. Average R2* value for IDC with FF (42.4±13.2 Hz) was significantly higher than that without FF (28.5±13.9 Hz) (P = 0.01). Spearman rank correlation suggested that the average R2* value correlated with the grade of HIF-1α and the ratio of peripheral to central microvessel density for IDCs (P < 0.001).ConclusionQuantification of tumour R2* using IDEAL is associated with the presence of FF and the overexpression of HIF-1α, and may therefore be useful in predicting hypoxia of breast carcinoma.Key Points• R2* value obtained by IDEAL correlates with the overexpression of HIF-1α.• R2* value obtained by IDEAL is associated with fibrotic focus.• R2* quantification may be useful in predicting hypoxia of breast carcinoma.


Journal of UOEH | 2008

[A case of low grade ductal carcinoma in situ of the breast with difficulties in making the preoperative diagnosis after detection by FDG-PET].

Yosuke Tsurudome; Takefumi Katsuki; Tetsumi Konishi; Jun Nagata; Yuzuru Inoue; Takahisa Nagata; Kazunori Shibao; Aiichiro Higure; Keiji Hirata; Yoshifumi Nakayama; Koji Okamoto; Naoki Nagata; Koji Yamaguchi

A 56-year-old woman underwent FDG-PET screening, which demonstrated delayed-phase uptake in the lower part of the left breast. The findings of mammography, ultrasonography, MRI and cytological examination were compatible with ductal carcinoma in situ (DCIS), but core needle biopsy showed no evidence of malignancy. Therefore, partial resection of the left breast with sentinel lymph node biopsy was performed to make a definite diagnosis. Histological examination showed that this tumor was low grade DCIS. FDG-PET is a very useful examination to detect malignant diseases, but it is quite difficult to distinguish them from benign ones. It is suggested that delayed-phase uptake of FDG-PET is useful for diagnosis of DCIS.


Anticancer Research | 2002

Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer.

Yoshifumi Nakayama; Nobuo Nagashima; Noritaka Minagawa; Yuzuru Inoue; Takefumi Katsuki; Koji Onitsuka; Tatsuhiko Sako; Keiji Hirata; Naoki Nagata; Hideaki Itoh


Experimental and Therapeutic Medicine | 2012

Prognostic significance of monocarboxylate transporter 4 expression in patients with colorectal cancer

Yoshifumi Nakayama; Takayuki Torigoe; Yuzuru Inoue; Noritaka Minagawa; Hiroto Izumi; Kimitoshi Kohno; Koji Yamaguchi


Anticancer Research | 2002

Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.

Noritaka Minagawa; Yoshifumi Nakayama; Keiji Hirata; Koji Onitsuka; Yuzuru Inoue; Naoki Nagata; Hideaki Itoh


Anticancer Research | 2003

Relationships between S-100 protein-positive cells and clinicopathological factors in patients with colorectal cancer.

Yoshifumi Nakayama; Yuzuru Inoue; Noritaka Minagawa; Takefumi Katsuki; Nobuo Nagashima; Koji Onitsuka; Yosuke Tsurudome; Tatsuhiko Sako; Keiji Hirata; Naoki Nagata; Hideaki Itoh

Collaboration


Dive into the Yuzuru Inoue's collaboration.

Top Co-Authors

Avatar

Keiji Hirata

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar

Takefumi Katsuki

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yosuke Tsurudome

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar

Aiichiro Higure

Primate Research Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge